Literature DB >> 3319460

Efficacy of 5-aminosalicylic acid enemas versus hydrocortisone enemas in ulcerative colitis.

M Campieri1, P Gionchetti, A Belluzzi, C Brignola, M Migaldi, G M Tabanelli, G Bazzocchi, M Miglioli, L Barbara.   

Abstract

A controlled trial has been carried out in order to compare the efficacy of enemas containing a high dosage of 5-ASA (4 g) versus enemas containing hydrocortisone 100 mg. The trial was conducted on 86 patients, 44 of whom received 5-ASA and 42 received hydrocortisone. The results were favorable in terms of clinical, sigmoidoscopic, and histologic criteria for 5-ASA treatment. Other aspects have been investigated, such as retrograde spread of enemas which have been shown to reach the left colon. No nephrotoxicity was detected. The long term experience confirmed the preliminary positive results.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3319460     DOI: 10.1007/BF01312467

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  18 in total

1.  CONTROLLED TRIAL OF SULPHASALAZINE IN THE TREATMENT OF ULCERATIVE COLITIS.

Authors:  A P DICK; M J GRAYSON; R G CARPENTER; A PETRIE
Journal:  Gut       Date:  1964-10       Impact factor: 23.059

2.  Comparison of corticosteroid and sulphasalazine therapy in ulcerative colitis.

Authors:  S C TRUELOVE; G WATKINSON; G DRAPER
Journal:  Br Med J       Date:  1962-12-29

3.  Biopsy studies in ulcerative colitis.

Authors:  S C TRUELOVE; W C RICHARDS
Journal:  Br Med J       Date:  1956-06-09

4.  Proceedings: Bacterial breakdown of sulphasalazine (salazopyrin).

Authors:  A K Azad Khan; H H Johnston; S C Truelove
Journal:  Gut       Date:  1975-10       Impact factor: 23.059

5.  Absorption, metabolism, and excretion of salicylazosulfapyridine in man.

Authors:  H Schröder; D E Campbell
Journal:  Clin Pharmacol Ther       Date:  1972 Jul-Aug       Impact factor: 6.875

6.  Retrograde spread of 5-aminosalicylic acid enemas in patients with active ulcerative colitis.

Authors:  M Campieri; G A Lanfranchi; C Brignola; G Bazzocchi; P Gionchetti; M R Minguzzi; I P Cappello; C Corbelli; S Boschi
Journal:  Dis Colon Rectum       Date:  1986-02       Impact factor: 4.585

7.  5-aminosalicylic acid for the treatment of inflammatory bowel diseases.

Authors:  M Campieri; G A Lanfranchi; C Brignola; G Bazzochi; P Gionchetti; M R Minguzzi; F Adami
Journal:  Gastroenterology       Date:  1985-09       Impact factor: 22.682

8.  Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype.

Authors:  K M Das; M A Eastwood; J P McManus; W Sircus
Journal:  N Engl J Med       Date:  1973-09-06       Impact factor: 91.245

9.  Topical administration of 5-aminosalicylic acid enemas in patients with ulcerative colitis. Studies on rectal absorption and excretion.

Authors:  M Campieri; G A Lanfranchi; S Boschi; C Brignola; G Bazzocchi; P Gionchetti; M R Minguzzi; A Belluzzi; G Labò
Journal:  Gut       Date:  1985-04       Impact factor: 23.059

10.  A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphazalazine (Salazopyrin).

Authors:  A S Dissanayake; S C Truelove
Journal:  Gut       Date:  1973-12       Impact factor: 23.059

View more
  5 in total

1.  Oral 4-aminosalicylic acid versus 5-aminosalicylic acid slow release tablets. Double blind, controlled pilot study in the maintenance treatment of Crohn's ileocolitis.

Authors:  S Schreiber; S Howaldt; A Raedler
Journal:  Gut       Date:  1994-08       Impact factor: 23.059

Review 2.  Inflammatory bowel disease.

Authors:  G M Van Rosendaal
Journal:  CMAJ       Date:  1989-07-15       Impact factor: 8.262

Review 3.  Mesalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in chronic inflammatory bowel disease.

Authors:  R N Brogden; E M Sorkin
Journal:  Drugs       Date:  1989-10       Impact factor: 9.546

4.  Real-World Data on Topical Therapies and Annual Health Resource Utilization in Hospitalized Swiss Patients with Ulcerative Colitis.

Authors:  Caroline Baehler; Beat Brüngger; Eva Blozik; Stephan R Vavricka; Alain M Schoepfer
Journal:  Inflamm Intest Dis       Date:  2019-08-07

Review 5.  Placebo response and remission rates in randomised trials of induction and maintenance therapy for ulcerative colitis.

Authors:  Vipul Jairath; G Y Zou; Claire E Parker; John K MacDonald; Turki AlAmeel; Mohammad Al Beshir; Majid A Almadi; Talal Al-Taweel; Nathan Ss Atkinson; Sujata Biswas; Thomas Chapman; Parambir S Dulai; Mark A Glaire; Daniël R Hoekman; Andreas Koutsoumpas; Elizabeth Minas; Mahmoud H Mosli; Mark Samaan; Reena Khanna; Simon Travis; Geert D'Haens; William J Sandborn; Brian G Feagan
Journal:  Cochrane Database Syst Rev       Date:  2017-09-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.